ArticleNeuropsychopharmacology reports2025
Investigating COVID-19-Induced Adjustment Disorder Among Iranian Patients With Multiple Sclerosis in Pandemic Time.
Article in Neuropsychopharmacology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe coronavirus disease 2019 (COVID-19) outbreak raised many concerns along with physical and mental health complications, including adjustment disorder (AD). Given the utmost importance of this issue for vulnerable groups, the present study was to investigate COVID-19-induced AD among Iranian patients living with multiple sclerosis (MS) in 2020.
methodsAdopting a cross-sectional research design, this study was performed on a statistical population of MS patients. Sampling was further done online via Porsline, as a survey tool, in Iran. In total, 247 patients were examined for the period of 2 months, recruiting a sociodemographic-medical information form and the Adjustment Disorder New Module (ADNM). As a final point, the data were analyzed using the SPSS Statistics software (ver. 26).
resultsThe MS patients' mean age was 36.10 ± 8.07 years. 82.6% of the participants were female. The AD mean score was also 44.09 ± 13.89, at the moderate level. In this line, a significant relationship was observed between AD among patients with MS and gender (p = 0.001), occupation (p = 0.009), a history of psychiatric disorders (p = 0.001), a history of taking psychiatric medications (p = 0.001), medical appointments canceled due to COVID-19 (p = 0.001), medication shortages amid COVID-19 (p = 0.018), a history of COVID-19 infection (p = 0.018), a history of polymerase chain reaction (PCR) test for COVID-19 (p = 0.042), worry about COVID-19 infection (p = 0.001), fear of familial COVID-19 infection (p = 0.001), and death of friends or relatives caused by COVID-19 (p = 0.025).
conclusionThe present study established that AD in the MS patients was at the moderate level, and it was even associated with some distinctive variables. So, data from multicenter studies are needed to achieve better recommendations regarding screening psychiatric disorders and supportive strategies in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.